Occurrence of individual adverse events.

<p>Occurrence of individual adverse events.</p

Patient attributes.

<p>PS: performance status, HER2: human epidermal growth factor receptor type 2, ER: estrogen receptor, PgR: progesterone receptor, EC: epirubicin/cyclophosphamide、TC: docetaxel/cyclophosphamide, TRZ: trastuzumab, DOC: docetaxel, LPR: leuprorelin, FUL: fulvestrant, CMF: cyclophosphamide/methotrexate/fluorouracil, nabPTX: nab-paclitaxel, 3w: 3 weeks, 4w: 4 weeks.</p><p>Patient attributes.</p

Comparison of the EQ-5D utility value and 5 dimensions before and after 1 course of outpatient chemotherapy.

<p>CT: chemotherapy,</p><p>*<i>p</i><0.05</p><p>Comparison of the EQ-5D utility value and 5 dimensions before and after 1 course of outpatient chemotherapy.</p

Comparison of the QOL-ACD total score and mean score for each subscale before and after 1 course of outpatient chemotherapy.

<p>CT: chemotherapy, mean±standard deviation,</p><p>*<i>p</i><0.05</p><p>Comparison of the QOL-ACD total score and mean score for each subscale before and after 1 course of outpatient chemotherapy.</p